Solid Biosciences Inc.
SLDBNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $8.1M | $13.6M | $0 |
| Operating income | −$179.2M | −$129.7M | −$104.3M | −$106.5M | −$72.3M | −$88.4M |
| Net income | −$174.3M | −$124.7M | −$96.0M | −$86.0M | −$72.2M | −$88.3M |
| Total assets | $232.5M | $188.7M | $164.9M | $260.3M | $232.4M | $171.2M |
| Total liabilities | $52.5M | $51.4M | $38.5M | $48.6M | $24.2M | $39.1M |
| Equity | $180.0M | $137.2M | $126.5M | $211.7M | $208.2M | $132.1M |
| EPS (diluted) | $-1.99 | $-3.06 | $-4.83 | $-10.10 | $-10.14 | $-25.50 |
| Shares out. | 77.5M | 37.8M | 19.6M | 110.5M | 85.1M | 46.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −96.8%
- Return on assets
- −75.0%
- Return on capital (ROCE)
- −90.0%
- Liabilities / assets
- 22.6%
- Debt / equity
- 0.29×
- Book value / share
- $2.32
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -10.16distress
- Accruals / assets
- −7.8%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2026-10-15Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
- Phase 1/2Recruitingreadout ~2027-05-06A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
- Phase 1Recruitingreadout ~2027-06A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
- Phase 1Recruitingreadout ~2028-03-21A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
- Phase 3Recruitingreadout ~2029-01A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Invus Global Management, LlcPassive (13G)May 5, 2026
- Blackrock, Inc.Passive (13G)Apr 27, 2026
- Ra Capital Management, L.P.Activist (13D)Mar 17, 2026
- Perceptive Advisors LlcActivist (13D)Mar 11, 2026
- Bcls Sb Investco, LpActivist (13D)Mar 10, 2026
- Vestal Point Capital, LpPassive (13G)Feb 17, 2026
- Adage Capital Management, L.P.Passive (13G)Feb 12, 2026
- Commodore Capital LpPassive (13G)Aug 14, 2025
- Camber Capital Management LpPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Smith Ian FDirector | Apr 2, 2026 | Option exercise | 3,441 | — |
| Cumbo AlexanderOfficer — President and CEO | Feb 13, 2026 | Option exercise | 30,031 | — |
| Hanrahan JessieOfficer — Chief Regulatory Officer | Feb 13, 2026 | Option exercise | 8,125 | — |
| Ganot IlanDirector | Feb 13, 2026 | Option exercise | 4,861 | — |
| Herzich PaulOfficer — Chief Technology Officer | Feb 13, 2026 | Option exercise | 7,187 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 9.1M | 6.8 | +3.3% |
| Apr 30, 2026 | 8.8M | 11.1 | -6.7% |
| Apr 15, 2026 | 9.4M | 9.4 | -6.0% |
| Mar 31, 2026 | 10.0M | 8.0 | +3.0% |
| Mar 13, 2026 | 9.8M | 4.3 | +2.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeApr 10, 2026
- Regulation FD disclosure · Other material eventMar 12, 2026
- Entered a material agreement · Results of operations · Unregistered equity sale · Other material eventMar 6, 2026
- Results of operations · Regulation FD disclosure · Other material eventNov 3, 2025
- Director / officer change · Shareholder voteJun 13, 2025
- Other material eventMay 15, 2025
- Entered a material agreement · Other material eventFeb 18, 2025
- Other material eventFeb 18, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.